Synthesis, antimicrobial activity and QSAR studies of 2,5-disubstituted benzoxazoles

SAR and QSAR in Environmental Research

Volumn 19, Issue 5-6, 2008, Pages 589-612

  Arisoy, M ^a   Temiz Arpaci, O ^a   Yildiz, I ^a   Kaynak Onurdag, F ^b   Aki, E ^a   Yalcin, I ^a   Abbasoglu, U ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Antibacterial activity; Antifungal activity; Benzoxazoles; QSAR

Indexed keywords

COMPUTATIONAL CHEMISTRY; REGRESSION ANALYSIS;

13C NMR; 1H NMR; ANTI-BACTERIAL ACTIVITY; ANTI-MICROBIAL ACTIVITY; ANTIFUNGAL ACTIVITIES; BENZOXAZOLE; QSAR; QSAR STUDIES; SYNTHESISED;

BACTERIA;

ISSATCHENKIA ORIENTALIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA;

EID: 53849089647     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10629360802348738     Document Type: Article

References (39)

1. A.M. Mohammed, M.G. Magdy, N.N. Magde, and A.H.B. Waleed, Novel analogues of sydnone: Synthesis, characterization and antibacterial evaluation, Arch. Pharm. 337 (2004), pp. 427-433.
2. V. Tomar, G. Bhattacharjee, K. Kumar, and A. Kumar, Synthesis and antimicrobial evaluation of new chalcones containing piperazine or 2,5-dichlorothiophene moiety, Bioorg. Med. Chem. Lett. 17 (2007), pp. 5321-5324.
3. M. Prudhomme, J. Guyot, and G. Jeminet, Semisynthesis of A 23187 (Calcimycin) analogs IV. Cation carrier properties in mitochondria of analogs with modified benzoxazole rings, J. Antibiot. 39 (1986), pp. 934-937.
4. H.K. Sarma, B.K. Sharma, and S.C. Tiwari, A novel calcimycin antibiotic from Gram-positive actinomycete frankia microsymbiont, Curr. Sci. 85 (2003), pp. 1401-1403.
5. J.P. Haansu, K.D. Klika, V.V. Ochaveranko, K. Pihlaja, K.K. Haatela, and P.M. Vourela, Isolation and biological activity of frankamide, J. Ind. Microbiol. Biotechnol. 27 (2001), pp. 62-66.
6. O.T. Arpaci, E.A. Sener, I. Yalcin, and N. Altanlar, Synthesis and antimicrobial activity of some 2-(p-substituted-phenyl)benzoxazol-5-yl- arylcarboxyamides, Arch. Pharm. 335 (2002), pp. 283-288.
7. I. Yildiz-Oren, B. Tekiner, I. Yalçin, O. Temiz-Arpaci, E. Aki-Şener, and N. Altanlar, Synthesis and antimicrobial activity of new 2-[p-substituted-benzyl]-5-[substituted-carbonylamino]benzoxazoles, Arch. Pharm. 337 (2004), pp. 402-410.
8. B. Tekiner-Gulbas, O. Temiz-Arpaci, I. Yildiz, and N. Altanlar, Synthesis and in vitro antimicrobial activity of new 2-[p-substituted-benzyl]-5-[substituted-carbonylamino]benzoxazoles, Eur. J. Med. Chem. 42 (2007), pp. 1293-1299.
9. O. Temiz-Arpaci, A. Ozdemir, I. Yalçin, I. Yildiz, E. Aki-Sener, and N. Altanlar, Synthesis and antimicrobial activity of some 5-[(2-morpholin-4-yl)acetamido] and/or 5-[2-(4-substitutedpiperazin-1-yl) acetamido]-2-(p-substituted-phenyl)benzoxazoles, Arch. Pharm. 338 (2005), pp. 105-111.
10. J. Koci, V. Klimesova, K. Waisser, J. Kaustova, H.M. Dahse, and U. Mollmann, Heterocyclic benzazole derivatives with antimycobacterial in vitro activity, Bioorg. Med. Chem. Lett. 12 (2002), pp. 3275-3278.
11. M. Ueki, K. Ueno, S. Miyadoh, K. Abe, K. Shibata, and M. Tanuguchi, UK-1, A novel cytotoxic metabolite from streptomyces sp. 517-02. I. Taxonomy, fermentation, isolation, physicochemical and biological properties, J. Antibiot. 46 (1993), pp. 1089-1094.
12. D.F. Shi, T.D. Bradshaw, S. Wrigley, C.J. McCall, P. Lelieveld, I. Fichtner, and M.F.G. Stevens, Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo, J. Med. Chem. 39 (1996), pp. 3375-3384.
13. M.R. DeLuca and S. Kerwin, The total synthesis of UK-1, Tetrahedron Lett. 38 (1997), pp. 199-202.
14. M.B. Reynolds, M.R. DeLuca, and S. Kerwin, The novel bis(benzoxazole) cytotoxic natural product UK-1 is a magnesium ion dependent DNA binding agent and inhibitor of human Topoisomerase II, Bioorg. Chem. 27 (1999), pp. 326-337.
15. Z.M. Nofal, M.I. El-Zahar, and S.S. Abd El-Karim, Novel coumarin derivatives with expected biological activity, Molecules 5 (2000), pp. 99-113.
16. W.S. Saari, J.S. Wai, T.E. Fisher, C.M. Thomas, J.M. Hoffman, C.S. Roomey, A.M. Smith, J.H. Jones, D.L. Bamberger, M.E. Goldman, O'brien J.A., Nunberg J.H., Quintero J.C., Schleif Q.A., Emini E.A., and Anderson P.S., Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one, J. Med. Chem. 35 (1992), pp. 3792-3802.
17. M.E. Goldman, J.A. O'brien, T.L. Ruffing, W.A. Schleif, V.V. Sardana, V.W. Byrnes, J.H. Condra, J.M. Hoffman, and E.A. Emini, A nonnucleoside reverse transcriptase inhibitor active on human immuno deficiency virus type 1 isolates resistant to related inhibitors, Antimicrob. Agents Chemother. 37 (1993), pp. 947-949.
18. J.M. Hoffman, A.M. Smith, C.S. Rooney, T.E. Fisher, J.S. Wai, C.M. Thomas, D.L. Bambmerger, J.L. Barnes, T.M. Williams, J.H. Jones, Olson B.D., O'brien J.A., Goldmah M.E., Nunberg J.H., Quintero J.C., Schleif W.A., Emini E.A., and Anderson P.S., Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 4. 3-2-(benzoxazol-2-yl) ethyl-5-ethyl-6-methylpyridin-2-(1H)-one and analogues, J. Med. Chem. 36 (1993), pp. 953-966.
19. R.T. Davey, R.L. Dewar, G.F. Reed, M.B. Vasudevachari, M.A. Polis, J.A. Kovacs, J. Falloon, R.E. Walker, H. Masur, S.E. Haneiwich, O'Neil D.G., Decker M.R., Metcalf J.A., Deloria M.A., Laskin O.L., Salzman N., and Lone H.C., Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661, Proc. Nat. Acad. Sci. USA. 90 (1993), pp. 5608-5612.
20. S. Staszewski, F.E. Massari, A. Kober, R. Göhler, S. Durr, K.W. Anderson, C.L. Schneider, J.A. Waterburry, K.K. Bakshi, and V.I. Taylor, Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor, J. Infect. Dis. 171 (1995), pp. 1159-1165.
21. D.B. Olsen, S.S. Carroll, J.C. Culberson, J.A. Shafer, and L.C. Kuo, Effect of template secondary structure on the inhibition of HIV-1 reverse transcriptase by a pyridinone non-nucleoside inhibitor, Nucl. Acids Res. 22 (1994), pp. 1437-1443.
22. W.R. Dolbier, C.R. Burkholder, and M. Medebielle, Synthesis of 2-(bromodifloromethyl)benzoxazole and 5-(bromodifloromethyl)-1,2,4-oxadiazoles, J. Fluorine Chem. 95 (1999), pp. 127-130.
23. J.S. Kim, Q. Sun, B. Gatto, C. Yu, A. Liu, L.F. Liu, and E.J. La Voie, Structure-activity relationships of benzimidazoles and related heterocycles as topoisomerase I poison, Bioorg. Med. Chem. 4 (1996), pp. 621-630.
24. D. Diez-Martin, N.R. Kotecha, S.V. Ley, S. Mantegani, J.C. Menendez, H.M. Organ, and A.D. White, Total synthesis of the ionophore antibiotic CP-61, 405 (routiennocin), Tetrahedron 48 (1992), pp. 7899-7938.
25. C. Hansch and A. Leo, Exploring QSAR: Fundamentals and Applications in Chemistry and Biochemistry, American Chemical Society, Washington, DC, 1995.
26. C. Hansch and T. Fujita, A method for the correlation of biological activity and chemical structure, J. Am. Chem. Soc. 86 (1964), pp. 1616-1626.
27. B. Tekiner-Gulbas, O. Temiz-Arpaci, E. Oksuzoglu, H. Eroglu, I. Yildiz, N. Diril, E. Aki-Sener, and I. Yalcin, QSAR of Genotoxic Active Benzazoles, SAR QSAR Environ. Res. 18 (2007), pp. 251-263.
28. E. Oksuzoglu, B. Tekiner-Gulbas, S. Alper, O. Temiz-Arpaci, T. Ertan, I. Yildiz, N. Diril, E. Sener-Aki, and I. Yalcin, Some Benzoxazoles and Benzimidazoles as DNA Topoisomerase I and II Inhibitors, J. Enzym. Inhib. Med. Chem. 23 (2008), pp. 37-42.
29. E. Oksuzoglu, O. Temiz-Arpaci, B. Tekiner-Gulbas, H. Eroglu, G. Sen, S. Alper, I. Yildiz, N. Diril, E. Aki-Sener, and I. Yalcin, A study on the genotoxic activities of some new benzoxazoles, Med. Chem. Res. 16 (2007), pp. 1-14.
30. Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS): Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard, M2-A9. Clinical and Laboratory Standarts Institute, 940 West Valley Road, Wayne, Pennsylvania, USA, 2006.
31. Clinical and Laboratory Laboratory Standards Institute (CLSI) (formerly NCCLS): Performance standards for antimicrobial susceptibility testing; 16th informational supplement. CLSI M100-S16. Clinical and Laboratory Standarts Institute, 940 West Valley Road, Wayne, PA, USA, 2006.
32. Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS): Reference Method for Broth Dilution Antifungal Susceptibility Testing Yeast; Approved Standard, M27-A. Clinical and Laboratory Standarts Institute, 940 West Valley Road, Wayne, Pennsylvania, USA, 2006.
33. C. Hansch, A. Leo, and D. Hoekman, Exploring QSAR: Hydrophobic, Electronic, and Steric Constants, American Chemical Society, Washington, DC, 1995.
34. 2, 2004.
35. I. Yildiz, T. Ertan, K. Bolelli, O. Temiz-Arpaci, I. Yalcin, and E. Aki, QSAR and pharmacophore analysis on amides against drug-resistant S. aureus, SAR QSAR Environ. Res. 19 (2008), pp. 101-113.
36. S. Wold, Validation of QSAR, Quant. Struct.-Act. Relat. 10 (1991), pp. 191-193.
37. J.O. Rawlings, Applied Regression Analysis, Wadsworth & Brooks/Cole, Pacific Grove, CA, 1988, pp. 186-189.
38. J.R. Graybill, The future of antifungal theraphy, Clin. Infect. Dis. 22 (1996), pp. 166-178.
39. H. Kubinyi, in QSAR Hansch Analysis and Related Approaches, R. Mannhold, P. Krogsgaard-Larsen, and H. Timmerman, eds., Wiley-VCH, Weinheim, 1993, p. 63.